沙库巴曲/缬沙坦与标准药物治疗对射血分数保留的心力衰竭患者血浆NT-proBNP浓度和次极量运动能力的影响:PARALLAX随机临床试验
这项24周随机双盲试验纳入2572例射血分数>40%的心力衰竭患者,比较沙库巴曲/缬沙坦与基于背景药物的个体化对照(依那普利、缬沙坦或安慰剂)。12周时沙库巴曲/缬沙坦组NT-proBNP降幅显著大于对照组(调整几何均值比0.84,95%CI 0.80-0.88,P<.001),但24周时6分钟步行距离、生活质量和NYHA心功能分级改善两组无显著差异。
要点
- 12周时沙库巴曲/缬沙坦组NT-proBNP降幅显著大于对照组,调整几何均值比0.84(95%CI 0.80-0.88,P<.001)。
- 24周时6分钟步行距离变化两组无显著差异:增加9.7 m vs 12.2 m,调整均值差-2.5 m(95%CI -8.5至3.5,P=.42)。
- 生活质量评分和NYHA心功能分级改善两组无显著差异。
核心结论
- 在射血分数>40%的心力衰竭患者中,与标准肾素-血管紧张素系统抑制剂治疗或安慰剂相比,沙库巴曲/缬沙坦治疗12周时血浆NT-proBNP水平降幅显著更大,但24周时6分钟步行距离无显著改善。
- 需进一步研究评估沙库巴曲/缬沙坦在这些患者中的潜在临床获益。
研究设计与样本
- 24周随机双盲平行组临床试验,2017年8月至2019年10月进行。
- 在32个国家396个中心筛查4632例患者,最终纳入2572例射血分数>40%、NT-proBNP升高、有结构性心脏病且生活质量下降的心力衰竭患者。
- 患者按1:1随机分配至沙库巴曲/缬沙坦组(n=1286)或基于背景药物的个体化对照组(n=1286),对照组使用依那普利、缬沙坦或安慰剂,根据既往是否使用肾素-血管紧张素系统抑制剂分层。
主要发现
- 2572例随机患者平均年龄72.6岁(SD 8.5岁),女性1301例(50.7%),2240例(87.1%)完成试验。
- 基线中位NT-proBNP水平:沙库巴曲/缬沙坦组786 pg/mL,对照组760 pg/mL。
- 12周时NT-proBNP较基线调整几何均值比:沙库巴曲/缬沙坦组0.82 pg/mL,对照组0.98 pg/mL,调整几何均值比0.84(95%CI 0.80-0.88,P<.001)。
- 24周时6分钟步行距离较基线中位变化:沙库巴曲/缬沙坦组增加9.7 m,对照组增加12.2 m,调整均值差-2.5 m(95%CI -8.5至3.5,P=.42),组间无显著差异。
- 堪萨斯城心肌病问卷临床总结评分平均变化:沙库巴曲/缬沙坦组12.3,对照组11.8,均值差0.52(95%CI -0.93至1.97),组间无显著差异;NYHA心功能分级改善:沙库巴曲/缬沙坦组23.6% vs 对照组24.0%,调整比值比0.98(95%CI 0.81-1.18)。
局限性
- 需进一步研究评估沙库巴曲/缬沙坦在这些患者中的潜在临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is limited evidence on the benefits of sacubitril/valsartan vs broader renin angiotensin system inhibitor background therapy on surrogate outcome markers, 6-minute walk distance, and quality of life in patients with heart failure and mildly reduced or preserved left ventricular ejection fraction (LVEF >40%). OBJECTIVE: To evaluate the effect of sacubitril/valsartan on N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, 6-minute walk distance, and quality of life vs background medication-based individualized comparators in patients with chronic heart failure and LVEF of more than 40%. DESIGN, SETTING, AND PARTICIPANTS: A 24-week, randomized, double-blind, parallel group clinical trial (August 2017-October 2019). Of 4632 patients screened at 396 centers in 32 countries, 2572 patients with heart failure, LVEF of more than 40%, elevated NT-proBNP levels, structural heart disease, and reduced quality of life were enrolled (last follow-up, October 28, 2019). INTERVENTIONS: Patients were randomized 1:1 either to sacubitril/valsartan (n = 1286) or to background medication-based individualized comparator (n = 1286), ie, enalapril, valsartan, or placebo stratified by prior use of a renin angiotensin system inhibitor. MAIN OUTCOMES AND MEASURES: Primary end points were change from baseline in plasma NT-proBNP level at week 12 and in the 6-minute walk distance at week 24. Secondary end points were change from baseline in quality of life measures and New York Heart Association (NYHA) class at 24 weeks. RESULTS: Among 2572 randomized patients (mean age, 72.6 years [SD, 8.5 years]; 1301 women [50.7%]), 2240 (87.1%) completed the trial. At baseline, the median NT-proBNP levels were 786 pg/mL in the sacubitril/valsartan group and 760 pg/mL in the comparator group. After 12 weeks, patients in the sacubitril/valsartan group (adjusted geometric mean ratio to baseline, 0.82 pg/mL) had a significantly greater reduction in NT-proBNP levels than did those in the comparator group (adjusted geometric mean ratio to baseline, 0.98 pg/mL) with an adjusted geometric mean ratio of 0.84 (95% CI, 0.80 to 0.88; P < .001). At week 24, there was no significant between-group difference in median change from baseline in the 6-minute walk distance with an increase of 9.7 m vs 12.2 m (adjusted mean difference, -2.5 m; 95% CI, -8.5 to 3.5; P = .42). There was no significant between-group difference in the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (12.3 vs 11.8; mean difference, 0.52; 95% CI, -0.93 to 1.97) or improvement in NYHA class (23.6% vs 24.0% of patients; adjusted odds ratio, 0.98; 95% CI, 0.81 to 1.18). The most frequent adverse events in the sacubitril/valsartan group vs the comparator group were hypotension (14.1% vs 5.5%), albuminuria (12.3% vs 7.6%), and hyperkalemia (11.6% vs 10.9%). CONCLUSIONS AND RELEVANCE: Among patients with heart failure and left ventricular ejection factor of higher than 40%, sacubitril/valsartan treatment compared with standard renin angiotensin system inhibitor treatment or placebo resulted in a significantly greater decrease in plasma N-terminal pro-brain natriuretic peptide levels at 12 weeks but did not significantly improve 6-minute walk distance at 24 weeks. Further research is warranted to evaluate potential clinical benefits of sacubitril/valsartan in these patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03066804.
引用
- Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021. PMID: 34783839. doi:10.1001/jama.2021.18463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。